Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The dynamics of HER2 status in esophageal adenocarcinoma.
Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM. Creemers A, et al. Among authors: van montfoort ml, van oijen mgh, van laarhoven hwm, van berge henegouwen mi. Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1. Oncotarget. 2018. PMID: 29928485 Free PMC article.
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Stockem CF, et al. Among authors: van montfoort ml. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023. Front Oncol. 2023. PMID: 37711193 Free PMC article.
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH, van Dijk N, van Dorp J, de Feijter JM, van Montfoort ML, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: van montfoort ml. Int J Cancer. 2022 Dec 1;151(11):2004-2011. doi: 10.1002/ijc.34125. Epub 2022 Jun 10. Int J Cancer. 2022. PMID: 35603905 Free article. Clinical Trial.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, van der Poel HG, Bruining A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, van den Broek M, Wessels LFA, Blank CU, van Rhijn BW, van der Heijden MS. van Dijk N, et al. Among authors: van montfoort ml. Nat Med. 2020 Dec;26(12):1839-1844. doi: 10.1038/s41591-020-1085-z. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046870 Clinical Trial.
The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.
Veerman H, Donswijk M, Bekers E, Olde Heuvel J, Bodar YJL, Boellaard TN, van Montfoort ML, van Moorselaar RJA, Oprea-Lager DE, van Leeuwen PJ, Vis AN, van der Poel HG. Veerman H, et al. Among authors: van montfoort ml. BJU Int. 2022 Mar;129(3):314-317. doi: 10.1111/bju.15664. Epub 2021 Dec 13. BJU Int. 2022. PMID: 34854204 Free PMC article. No abstract available.
A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.
van Dorp J, van Montfoort ML, van Dijk N, Hofland I, de Feijter JM, Bergman AM, Hendricksen K, van der Poel HG, van Rhijn BWG, van der Heijden MS. van Dorp J, et al. Among authors: van montfoort ml. Clin Genitourin Cancer. 2022 Apr;20(2):e173-e179. doi: 10.1016/j.clgc.2021.12.004. Epub 2021 Dec 10. Clin Genitourin Cancer. 2022. PMID: 35016887 No abstract available.
22 results